Abstract
Purpose Dysregulation of systemic calcium homeostasis during malignancy is common in most patients with high grade tumors. However, it remains unclear whether single nucleotide polymorphisms (SNPs) that alter the sensitivity of the calcium-sensing receptor (CaSR) to circulating calcium are associated with primary and/or secondary neoplasms at specific pathological sites in patients of European and African ancestry.
Methods Multivariable logistic regression models were used to analyze the association of CASR SNPs with circulating calcium, parathyroid hormone, vitamin D, and primary and secondary neoplasms.
Results Circulating calcium is associated with an increased risk for breast, prostate, and skin cancers. In patients of European descent, the rs1801725 CASR SNP is associated with bone-related cancer phenotypes, deficiency of humoral immunity, and a higher risk of secondary neoplasms in the lungs and bone. Interestingly, circulating calcium levels are higher in homozygous patients for the inactivating CASR variant at rs1801725 (TT genotype), and this is associated with a higher risk of secondary malignancies.
Conclusions Breast, prostate, and skin cancer patients with homozygous inactivating variants (TT genotype) at the CASR rs1801725 locus have a higher risk of developing secondary neoplastic lesions in the lungs and bone, due in part, to cancer-induced hypercalcemia and/or tumor immune suppression.
- cancer-induced hypercalcemia
- calcium-sensing receptor
- A986S
- rs1801725
- metastasis
- phenome-wide association study
- electronic health records
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KVA is funded by the NIH 5T32GM007628 training grant. HKB is funded by the NIH R25 GM059994 and U54 CA163069 grants. AS is supported by SC1 CA211030, P50 CA095103, U54 MD007593. This study used resources from the Advanced Computing Center for Research and Education and the Synthetic Derivative at Vanderbilt University Medical Center which are supported by Shared Instrumentation Grant S10RR025141 and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data repositories are supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vumc.org/biovu-funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of de-identified EHR data for this project was approved by the VUMC Institutional Review Board under IRB #190418. The research was conducted in accordance with the principles of the Helsinki Declaration.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding/Support: KVA is funded by the NIH 5T32GM007628 training grant. HKB is funded by the NIH R25 GM059994 and U54 CA163069 grants. AS is supported by SC1 CA211030, P50 CA095103, U54 MD007593. This study used resources from the Advanced Computing Center for Research and Education and the Synthetic Derivative at Vanderbilt University Medical Center which are supported by Shared Instrumentation Grant S10RR025141 and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data repositories are supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vumc.org/biovu-funding
Data Availability
The data that support the findings of this study are available from Vanderbilt University Medical Center, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of Vanderbilt University Medical Center.
